Methods for antifungal combination studies in vitro and in vivo in animal models;Techniques d'étude des associations d'antifongiques in vitro et in vivo chez l'animal

Journal de Mycologie Medicale

Volumn 13, Issue 2, 2003, Pages 73-85

  Dannaoui, E ^a   Lortholary, O ^a   Dromer, F ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Antifungals; Combination; MIC

Indexed keywords

ANTIFUNGAL AGENT;

ANIMAL MODEL; BROTH MICRODILUTION CHECKERBOARD TECHNIQUE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; FUNGUS CULTURE; FUNGUS GROWTH; GROWTH INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MYCOSIS; NONHUMAN; REVIEW;

ANIMALIA; FUNGI; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0037774755     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Afeltra J, Dannaoui E, Meis JF, Rodriguez-Tudela JL, Verweij PE. In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans. Antimicrob Agents Chemother 2002; 46:3323-6.
2. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002;46-245-7.
3. Barchiesi F, Di Francesco LF, Compagnucci P, Arzeni D, Giacometti A, Scalise G. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J Antimicrob Chemother 1998;41:59-65.
4. Barchiesi F, Falconi Di Francesco L, Scalise G. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrob Agents Chemother 1997;41:1812-4.
5. Barchiesi F, Gallo D, Caselli F, Di Francesco LF, Arzeni D, Giacometti A et al. In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. J Antimicrob Chemother 1999;44:65-70.
6. Barchiesi F, Schimizzi AM, Caselli F, Novelli A, Fallani S, Giannini D et al. Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother 2000;44:2435-41.
7. Barchiesi F, Schimizzi AM, Najvar LK, Bocanegra R, Caselli F, Di Cesare S et al. Interactions of posaconazole and flucytosine against Cryptococcus neoformans. Antimicrob Agents Chemother 2001;45:1355-9.
8. Barrizal K, Gill CJ, Abruzzo GK, Flattery AM, Kong L, Scott PM et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997;41:2326-32.
9. Becker MJ, De Marie S, Fens MH, Hop WC, Verbrugh HA, Bakker-Woudenberg IA. Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by combination of AmBisome with Fungizone as assessed by several parameters of antifungal response. J Antimicrob Chemother 2002;49:813-20.
10. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979;301-126-31.
11. Berenbaum MC. Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunol 1977;28:1-18.
12. Berenbaum MC. A method for testing for synergy with any number of agents. J Infect Dis 1978;137:122-30.
13. Bertout S, Lebecq JC, Bastide JM, Mallié M. Evaluation de l'activité antifongique in vitro des associations flucytosine-fluconazole et flucytosine-amphȯtéricine B sur diverses espèces de Candida. J Mycol Méd 2002;12:157-62.
14. Chin NX, Weitzman I, Della-Latta P. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 1997;41:850-2.
15. Chiou CC, Mavrogiorgos N, Tillem E, Hector R, Walsh TJ. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother 2001;45:3310-21.
16. Clancy CJ, Nguyen MH. The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis. J Antimicrob Chemother 1998;41:127-30.
17. Clancy CJ, Yu YC, Lewin A, Nguyen MH. Inhibition of RNA synthesis as a therapeutic strategy against Aspergillus and Fusarium: demonstration of in vitro synergy between rifabutin and amphotericin B. Antimicrob Agents Chemother 1998;42:509-13.
18. Dannaoui E. Tests de déermination de la sensibilité aux antifongiques, apport des modèes animaux. In: Les annales de l'Institut Pasteur/actualité, Edited by F. Dromer. Elsevier, Paris: 2003, in press.
19. Dannaoui E, Afeltra J, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother 2002;46:2708-11.
20. Del Poeta M, Cruz MC, Cardenas ME, Perfect JR, Heitman J. Synergistic antifungal activities of bafilomycin A(1), flconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformns. Antimicrob Agents Chemother 2000;44:739-46.
21. Diamond DM, Bauer M, Daniel BE, Leal MA, Johnson D, Williams BK et al. Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis. Antimicrob Agents Chemother 1998;42:528-33.
22. Ding JC, Bauer M, Diamond DM, Leal MA, Johnson D, Williams BK et al. Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob Agents Chemother 1997;41:1589-93.
23. Drusano GL, D'Argenio DZ, Symonds W, Bilello PA, McDowell J, Sadler B et al. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob Agents Chemother 1998;42:2153-9.
24. Ernst EJ, Klepser ME, Pfaller MA. In vitro interaction of fluconazole and amphotericin B administered sequentially against Candida albicans: effect of concentration and exposure time. Diagn Microbiol Infect Dis 1998;32:205-10.
25. Ernst EJ, Klepser ME, Pfaller MA. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 2000;44:1108-11.
26. Ernst EJ, Yodoi K, Roling EE, Klepser ME. Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods. Antimicrob Agents Chemother 2002;46:578-81.
27. Franzot SP, Casadevall A. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother 1997;41:331-6.
28. Ghannoum MA, Fu Y, Ibrahim AS, Mortara LA, Shafiq MC, Edwards JE Jr. et al. In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrob Agents Chemother 1995;39:2459-65.
29. Graybill JR. The role of murine models in the development of antifungal therapy for systemic mycoses. Drug Resist Updat 2000;3:364-83.
30. Graybill JR, Najvar LK, Holmberg JD, Luther MF. Fluconazole, D0870, and flucytosine treatment of disseminated Candida tropicalis infections in mice. Antimicrob Agents Chemother 1995;39:924-9.
31. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995;47:331-85.
32. Greco WR, Park HS, Rustum YM. Application of a new approach for the quantitation of drug synergism to the combination of cisdiamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res 1990;50:5318-27.
33. Guarro J, Pujol I, Mayayo E. In vitro and in vivo experimental activities of antifungal agents against Fusarium solani. Antimicrob Agents Chemother 1999;43:1256-7.
34. Haynes RR, Connolly PA, Durkin MM, LeMonte AM, Smedema ML, Brizendine E et al. Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection. J Infect Dis 2002;185:1830-2.
35. Iovannitti C, Negroni R, Bava J, Finquelievich J, Kral M. Itraconazole and flucytosine+itraconazole combination in the treatment of experimental cryptococcosis in hamsters. Mycoses 1995;38:449-52.
36. Kartalija M, Kaye K, Tureen JH, Liu Q, Tauber MG, Elliott BR et al. Treatment of experimental cryptococcal meningitis with fluconazole: impact of dose and addition of flucytosine on mycologic and pathophysiologic outcome. J Infect Dis 1996;173:1216-21.
37. Keele DJ, DeLallo VC, Lewis RE, Ernst EJ, Klepser ME. Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology. Diagn Microbiol Infect Dis 2001;41:121-6.
38. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002;46:2564-8.
39. Kontoyiannis DP, Lewis RE, Sagar N, May G, Prince RA, Rolston KV. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E- test-based strategy. Antimicrob Agents Chemother 2000;44:2915-8.
40. Kuipers ME, de Vries HG, Eikelboom MC, Meijer DK, Swart PJ. Synergistic fungistatic effects of lactoferrin in combination with anti-fungal drugs against clinical Candida isolates. Antimicrob Agents Chemother 1999;43:2635-41.
41. Larsen RA, Bauer M, Weiner JM, Diamond DM, Leal ME, Ding JC et al. Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother 1996; 40:2178-82.
42. LeMonte AM, Washum KE, Smedema ML, Schnizlein-Bick C, Kohler SM, Wheat LJ. Amphotericin B combined with itraconazole or fluconazole for treatment of histoplasmosis. J Infect Dis 2000;182:545-50.
43. Lewis RE, Diekema DJ, Messer SA, Pfaller MA, Klepser ME. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother 2002;49:345-51.
44. Lewis RE, Lund BC, Klepser ME, Ernst EJ, Pfaller MA. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob Agents Chemother 1998;42:1382-6.
45. Lewis RE, Prince RA, Chi J, Kontoyiannis DP. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2002;46:3208-14.
46. Li RK, Rinaldi MG. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob Agents Chemother 1999;43:1401-5.
47. Louie A, Banerjee P, Drusano GL, Shayegani M, Miller MH. Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans. Antimicrob Agents Chemother 1999;43:2841-7.
48. Louie A, Kaw P, Banerjee P, Liu W, Chen G, Miller MH. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis. Antimicrob Agents Chemother 2001;45:485-94.
49. Louie A, Liu W, Miller DA, Sucke AC, Liu QF, Drusano GL et al. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. Antimicrob Agents Chemother 1999;43:2831-40.
50. Lyman CA, Gonzalez C, Schneider M, Lee J, Walsh TJ. Effects of the hematoregulatory peptide SK & F 107647 alone and in combination with amphotericin B against disseminated candidiasis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1999;43:2165-9.
51. Maesaki S, Marichal P, Hossain MA, Sanglard D, Vanden Bossche H, Kohno S. Synergic effects of tactolimus and azole antifungal agents against azole-resistant Candida albican strains. J Antimicrob Chemother 1998;42:747-53.
52. Marchetti O, Entenza JM, Sanglard D, Bille J, Glauser MP, Moreillon P. Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob Agents Chemother 2000;44:2932-8.
53. Marchetti O, Moreillon P, Glauser MP, Bille J, Sanglard D. Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother 2000;44:2373-81.
54. Meletiadis J, Mels JF, Mouton JW, Verweij PE. Methodological issues related to antifungal drug interaction modelling for filamentous fungi. Rev Med Microbiol 2002;13:101-17.
55. Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003;47:106-17.
56. Meletiadis J, Mouton JW, Rodriguez-Tudela JL, Meis JF, Verweij PE. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans. Antimicrob Agents Chemother 2000;44:470-2.
57. Moneib NA. In-vitro activity of commonly used antifungal agents in the presence of rifampin, polymyxin B and norfloxacin against Candida albicans. J Chemother 1995;7:525-9.
58. Mosquera J, Sharp A, Moore CB, Warn PA, Denning DW. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J Antimicrob Chemother 2002;50:189-94.
59. Murai T, Nakamura Y, Kano R, Watanabe S, Hasegawa A. Susceptibility testing of Malassezia pachydermatis using the urea broth microdilution method. Mycoses 2002;45:84-7.
60. Nakajima R, Kitamura A, Someya K, Tanaka M, Sato K. In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Antimicrob Agents Chemother 1995;39:1517-21.
61. Nash JD, Burgess DS, Talbert RL. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans. J Med Microbiol 2002;51:105-9.
62. Nguyen MH, Barchiesi F, McGough DA, Yu VL, Rinaldi MG. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother 1995;39:1691-5.
63. Nguyen MH, Clancy CJ, Yu YC, Lewin AS. Potentiation of antifungal activity of amphotericin B by azithromycin against Aspergillus species. Eur J Clin Microbiol Infect Dis 1997;16:846-8.
64. Nguyen MH, Najvar LK, Yu CY, Graybill JR. Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. Antimicrob Agents Chemother 1997;41:1120-3.
65. Oh KB, Yang HC, Matsuoka H, Yamamoto A, Kurata H. Combined effect of amphotericin B and flucytosine on hyphal growth of Candida albicans estimated at a single hypha level. J Med Vet Mycol 1995;33:191-5.
66. Ortoneda M, Capilla J, Pujol I, Pastor FJ, Mayayo E, Fernandez-Ballart J et al. Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans. J Antimicrob Chemother 2002;49:525-9.
67. Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002;46:3039-41.
68. Perea S, Gonzalez G, Fothergill AW, Sutton DA, Rinaldi MG. In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. J Clin Microbiol 2002;40:1831-3.
69. Pina-Vaz C, Sansonetty F, Rodrigues AG, Martinez-De-Oliveira J, Fonseca AF, Mardh PA. Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species. J Med Microbiol 2000;49:831-40.
70. Polak A. The past, present and future of antimycotic combination therapy. Mycoses 1999;42:355-70.
71. Prichard MN Shipman C Jr. A three-dimensional model to analyze drug-drug interactions. Antiviral Res 1990;14:181-205.
72. Rath PM, Hulsewede JW, Ansorg R. Imipenem inhibits in vitro activity of amphotericin B directed against Aspergillus fumigatus. Zentralbl Bakteriol 1995;283:69-78.
73. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997;24:235-47.
74. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000;30:662-78.
75. Rodero L, Cordoba S, Cahn P, Hochenfellner F, Davel G, Canteros C et al. In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy. J Antimicrob Chemother 2000;45:239-42.
76. Roling EE, Klepser ME, Wasson A, Lewis RE, Ernst EJ, Pfaller MA. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis 2002;43:13-7.
77. Ryder NS, Leitner I. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species. Med Mycol 2001;39:91-5.
78. Sanati H, Ramos CF, Bayer AS, Ghannoum MA. Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models. Antimicrob Agents Chemother 1997;41:1345-8.
79. Scheven M, Schwegler F. Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Antimicrob Agents Chemother 1995;39:1779-83.
80. Scott EM, Tariq VN, McCrory RM. Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro. Antimicrob Agents Chemother 1995;39:2610-4.
81. Sepkowitz KA, Raffalli J, Riley L, Kiehn TE, Armstrong D. Tuberculosis in the AIDS era. Clin Microbiol Rev 1995;8:180-99.
82. Siau H, Kerridge D. The effect of antifungal drugs in combination on the growth of Candida glabrata in solid and liquid media. J Antimicrob Chemother 1998;41:357-66.
83. Simonetti G, Villa A, Simonetti N. Enhanced contact activity of fluconazole in association with antioxidants against fluconazole-resistant organisms. J Antimicrob Chemother 2002;50:257-9.
84. Snyder S, D'Argenio DZ, Weislow O, Bilello JA, Drusano GL. The triple combination indinavir-zidovudine-lamivudine is highly synergistic. Antimicrob Agents Chemother 2000;44:1051-8.
85. Stevens DA. Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens. Antimicrob Agents Chemother 2000;44:2547-8.
86. Sugar AM, Hitchcock CA, Troke PF, Picard M. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob Agents Chemother 1995;39:598-601.
87. Sugar AM, Liu XP. Interactions of itraconazole with amphotericin B in the treatment of murine invasive candidiasis. J Infect Dis 1998;177:1660-3.
88. Sugar AM, Liu XP. Combination antifungal therapy in treatment of murine pulmonary mucormycosis: roles of quinolones and azoles. Antimicrob Agents Chemother 2000;44:2004-6.
89. Sugar AM, Liu XP, Chen RJ. Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs. Antimicrob Agents Chemother 1997;41:2518-21.
90. Suhnel J. Evaluation of synergism or antagonism for the combined action of antiviral agents. Antiviral Res 1990;13:23-39.
91. Tanida T, Rao F, Hamada T, Ueta E, Osaki T. Lactoferrin peptide increases the survival of Candida albicans-inoculated mice by upregulating neutrophil and macrophage functions, especially in combination with amphotericin B and granulocyte-macrophage colony-stimulating factor. Infect Immun 2001;69:3883-90.
92. Tariq VN, Scott EM, McCain NE. Use of decimal assay for additivity to demonstrate synergy in pair combinations of econazole, nikkomycin Z, and ibuprofen against Candida albicans in vitro. Antimicrob Agents Chemother 1995;39:2615-9.
93. Te Dorsthorst DT, Verweij PE, Meis JF, Punt NC, Mouton JW. Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-susceptible and -resistant Aspergillusfumigatus isolates. Antimicrob Agents Chemother 2002;46:702-7.
94. Te Dorsthorst DT, Verweij PE, Meletiadis J, Bergervoet M, Punt NC, Meis JF et al. In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob Agents Chemother 2002;46:2982-9.
95. Wakabayashi H, Abe S, Teraguchi S, Hayasawa H, Yamaguchi H. Inhibition of hyphal growth of azole-resistant strains of Candida albicans by triazole antifungal agents in the presence of lactoferrin-related compounds. Antimicrob Agents Chemother 1998;42:1587-91.
96. Walsh TJ, Peter J, McGough DA, Fothergill AW, Rinaldi MG, Pizzo PA. Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother 1995;39:1361-4.
97. Weig M, Muller FM. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2001;45:966-8.
98. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. Jama 2002;288:222-35.